- Home
- ALNY vs ED Comparison
ALNY vs ED Comparison
Compare ALNY & ED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALNY | ED |
|---|---|---|
| Founded | 2002 | 1884 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8B | 39.5B |
| IPO Year | 2004 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ALNY | ED |
|---|---|---|
| Price | $297.61 | $111.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 28 | 13 |
| Target Price | ★ $471.00 | $107.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.26% |
| EPS Growth | ★ 206.88 | 7.63 |
| EPS | 2.33 | ★ 5.64 |
| Revenue | $1,037,418,000.00 | ★ $16,918,000,000.00 |
| Revenue This Year | $52.67 | $9.18 |
| Revenue Next Year | $31.48 | $4.49 |
| P/E Ratio | $132.48 | ★ $19.71 |
| Revenue Growth | ★ 22.88 | 10.89 |
| 52 Week Low | $246.00 | $94.96 |
| 52 Week High | $495.55 | $116.23 |
Technical Indicators
Market Signals| Indicator | ALNY | ED |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 50.28 |
| Support Level | N/A | $108.67 |
| Resistance Level | $337.95 | $115.27 |
| Average True Range (ATR) | 12.33 | 1.87 |
| MACD | -1.64 | 0.02 |
| Stochastic Oscillator | 17.28 | 66.67 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.